Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Posted by Alanna Baker on Mar 13th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00. Following the completion of the transaction, the president now owns 2,841,260 shares of the company’s stock, valued at $29,122,915. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Songjiang Ma also recently made the following trade(s):

On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00.
On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total transaction of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.

Gyre Therapeutics Price Performance

Shares of GYRE opened at $11.67 on Thursday. The company’s fifty day moving average is $11.24 and its two-hundred day moving average is $12.32. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $19.96.

Analyst Upgrades and Downgrades

Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock.

Check Out Our Latest Stock Report on Gyre Therapeutics

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC acquired a new position in shares of Gyre Therapeutics during the 3rd quarter worth $47,000. Wells Fargo & Company MN grew its stake in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares during the period. Bank of America Corp DE grew its stake in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after purchasing an additional 1,996 shares during the period. Barclays PLC grew its stake in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after acquiring an additional 1,389 shares during the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.